Q3 FY23 Earnings Presentation

Medical Surgical 3% growth (ex. vents, China) driven by SI share recapture and improved product availability Surgical Innovations (SI) • Significant sequential share recapture in SI due to improved product availability • LSD decline in Advanced Surgical Instruments driven by ongoing China VBP in Stapling, partially offset by MSD growth in Energy; ex-China, Sl growth in MSD 33% RGR | $712M -7.7% Y/Y Rep -3.0% Y/Y Org -0.3% ex-Vents Y/Y Org $2,137M -6.7 Y/Y Rep -1.6% Y/Y Org -0.7% ex-Vents Y/Y Org • LSD growth in Hernia & Wound Management driven by V-LocTM Barbed Sutures despite procedure softness in China Opened strategic markets with Hugo TM system installations in EU and APAC, including repeat orders Started South Korea "Hello Hugo" pre-market clinical trial for urology and general surgery indications U.S. IDE urology clinical trial began in December 2022 and continues to progress as planned Respiratory, Gastrointestinal, & Renal (RGR) Patient Monitoring: LSD Nellcor™ pulse oximetry growth on tough Y/Y comps; HSD OUS growth Respiratory Interventions: High-20s decline in ventilators (final quarter of difficult Y/Y comps), slightly offset by HSD growth in Endotracheal Tubes Gastrointestinal: Mid-teens growth in chronic & colorectal driven by strong US GI Genius TM performance Renal Care Solutions: HSD decline given product availability challenges 0- SonicisionTM 7mm Ultrasonic curved jaw Hugo™ RAS System¹ Gl Genius™ Intelligent endoscopy module 1) Hugo TM is not available in the U.S. 11 Q3 FY23 Earnings Presentation | February 21, 2023 ......67% SI | $1,425M -6.2% Y/Y Rep -0.9% Y/Y Org Operating Unit Growth Surgical Innovations LSD Gastrointestinal HSD Respiratory Interventions LDD Patient Monitoring Renal Care Solutions LSD HSD Medtronic

View entire presentation